Table 1.
Patient Characteristics at Baseline (n=23)
| All Patients (n=23) | Biologics-Naïve (n=13) | Previous Mepolizumab (+) (n=10) | p value Between Two Groups | |
|---|---|---|---|---|
| Male, n (%) | 10 (43) | 5 (38) | 5 (50) | 0.69* |
| Age (years), mean (SD) (range) | 59.8 (10.3) (38–75) | 60.6 (9.8) (43–75) | 58.8 (11.4) (38–72) | 0.73† |
| Duration of disease (years), mean (SD) (range) | 21.9 (12.7) (6–54) | 23.6 (13.9) (6–54) | 19.4 (11.2) (6–36) | 0.57† |
| Body mass index (kg/m2), mean (SD) | 23.1 (4.6) | 24.6 (4.8) | 21.2 (3.6) | 0.07† |
| Smoking (never / former / current), n | 15 / 7 / 1 | 7 / 5 / 1 | 8 / 2 / 0 | 0.37‡ |
| Initial treatments use | ||||
| ―ICS/LABA, n (%) | 23 (100) | 13 (100) | 10 (100) | ― |
| ―ICS dose (µg), mean (SD) | 1503 (547) | 1491 (628) | 1520 (454) | 0.66† |
| ―LAMA, n (%) | 14 (61) | 8 (62) | 6 (60) | >0.99* |
| ―LTRA, n (%) | 19 (83) | 10 (77) | 9 (90) | 0.60* |
| ―xanthine derivative, n (%) | 15 (65) | 8 (62) | 7 (70) | >0.99* |
| ―maintenance therapy of OCS, n (%) | 9 (39) | 6 (46) | 3 (30) | 0.67* |
| ―daily dose of OCS (mg), mean (range) | 6.0 (2.5–15) (n=9) | 6.8 (4–15) (n=6) | 4.5 (2.5–6) (n=3) | 0.50† |
| Comorbidities | ||||
| ―ECRS, n (%) | 19 (83) | 11 (85) | 8 (80) | >0.99* |
| ―EGPA, n (%) | 4 (17) | 1 (8) | 3 (30) | 0.28* |
| ―AERD, n (%) | 3 (13) | 3 (23) | 0 (0) | 0.23* |
| ―chronic eosinophilic pneumonia, n (%) | 3 (13) | 0 (0) | 3 (30) | 0.07* |
| Previous biologics | ||||
| ―omalizumab, n (%) / mean (range) (month) | 3 (13) / 39.7 (11–88) | ― | 3 (30) / 39.7 (11–88) | ― |
| ―mepolizumab, n (%) / mean (range) (month) | 10 (43) / 19.7 (3–35) | ― | 10 (100) / 19.7 (3–35) | ― |
| Observation period (months), mean (range) | 38.3 (24–49) | 37.9 (24–47) | 38.7 (24–49) | 0.76† |
Notes: Data are presented as n (%) or mean (standard deviation), unless otherwise stated. *Fisher’s exact test, †Mann–Whitney U-test, ‡Chi-square test.
Abbreviations: AERD, aspirin-exacerbated respiratory disease; ECRS, eosinophilic chronic rhinosinusitis; EGPA, eosinophilic granulomatosis with polyangiitis; ICS, inhaled corticosteroid; LABA, long-acting β-2 agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroids; SD, standard deviation.